JNJ-2113 is under clinical development by Johnson & Johnson and currently in Phase III for Psoriatic Arthritis.

Steqeyma is approved for adult and pediatric patients with plaque psoriasis and active psoriatic arthritis as well as adults ...

Chronic kidney disease is not uncommon among patients with PsA, with risk factors including diabetes and NSAID use, while ...

Stagnant sales for Bristol Myers Squibb’s Sotyktu have raised questions about whether the tyrosine kinase 2 (TYK2) inhibitor ...

Differences in how men and women manifest and experience psoriatic arthritis suggest it’s time to think of patient sex as a ...

FDA confirms end of Zepbound shortage, but announces new shortages for other medications, including Humira biosimilar and painkillers. Details here.

Both trials recruited patients with psoriatic arthritis who had not previously received biologic disease-modifying antirheumatic drugs.

Secukinumab is under clinical development by Novartis and currently in Phase II for Unspecified Dermatological Disorders.

A research team from the University of Central Florida's College of Medicine conducted a study of patient perceptions of ...